source
- GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisitionGSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials. The move comes as the company proceeds with its planned $…
- Dimerix acquires Mission’s acute kidney injury candidate for $5 million upfrontDimerix announced it has signed a deal to acquire a kidney injury drug candidate from Mission Therapeutics. The asset is ready to enter Phase 2 trials for the treatment of acute kidney injury. Und…